Available online 23 September 2022, 115820

Ceftaroline was tested against 9,268 Staphylococcus aureus from 33 US hospitals

Susceptibility results were stratified by infection type and resistance profile

Ceftaroline susceptibility ranged from 95.4% (pneumonia) to 98.5% (SSSI)

Ceftaroline retained potent and broad-spectrum activity against MRSA (93.4%S)

Highest ceftaroline MIC value was 2 mg/L

Ceftaroline and comparators were tested against 9,268 Staphylococcus aureus isolates from 33 United States hospitals (2018-2020). Ceftaroline (MIC50/90, 0.25/1 mg/L) susceptibility ranged from 95.4% (pneumonia) to 98.5% (skin and skin structure) and was 97.2% overall. Ceftaroline retained potent and broad-spectrum activity against methicillin-resistant isolates, with a 93.4% overall susceptibility.

MRSA

skin and skin structure infection

pneumonia

ceftaroline

Staphylococcus aureus

© 2022 Published by Elsevier Inc.